Trials / Completed
CompletedNCT01107587
Study to Assess the Safety of GSK Biologicals' Liquid Human Rotavirus Vaccine in Healthy Infants
Reactogenicity and Safety of Two Doses of GlaxoSmithKline (GSK) Biologicals' Oral Live Attenuated Liquid Human Rotavirus (HRV) Vaccine 444563, in Healthy Infants
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 50 (actual)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- All
- Age
- 6 Weeks – 16 Weeks
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to assess the reactogenicity and safety of GSK Biologicals' liquid human rotavirus vaccine in healthy infants aged 6 to 16 weeks at the time of the first dose of vaccination.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | GSK Biologicals' human rotavirus vaccine 444563 | Oral, two doses. |
| BIOLOGICAL | Placebo | Oral, two doses. |
Timeline
- Start date
- 2010-04-13
- Primary completion
- 2010-06-28
- Completion
- 2010-06-28
- First posted
- 2010-04-21
- Last updated
- 2017-05-19
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT01107587. Inclusion in this directory is not an endorsement.